This article is more than 5 years old. Information may no longer be current.
Cyclophotocoagulation effective in lowering IOP in keratoprosthesis refractory glaucoma patients
J Glaucoma. 2009;18(4):321-324.
Click Here to Manage Email Alerts
Keratoprosthesis patients who have uncontrolled glaucoma benefit from diode laser transscleral cyclophotocoagulation at different stages, with lowered IOP and no rise in glaucoma medications, a study found.
"[Diode laser transscleral cyclophotocoagulation] has beneficial long-term effects in the control of IOP and can be considered in the management of keratoprosthesis patients with refractory glaucoma," the study authors said.
They conducted a study of 18 eyes of 18 patients. Of those, 11 eyes were diagnosed with glaucoma before keratoprosthesis surgery and seven eyes were diagnosed after surgery. Keratoprosthesis type 1 was used in the majority of cases in the study. Seventeen patients had an Ahmed glaucoma valve implanted.
Three patients had diode laser transscleral cyclophotocoagulation before keratoprosthesis surgery; one had the procedure during surgery; and 14 had the procedure after surgery.
Researchers found that mean postoperative IOP was reduced significantly at every follow-up up to 48 months after diode laser transscleral cyclophotocoagulation. There was no statistically significant difference in number of postop glaucoma medications.
While diode laser transscleral cyclophotocoagulation had to be repeated in six eyes, only two eyes had complications.